Risks associated with the environmental release of pharmaceuticals on the US Food and Drug Administration "flush list"

被引:34
|
作者
Khan, Usman [1 ]
Bloom, Raanan A. [2 ]
Nicell, James A. [3 ]
Laurenson, James P. [2 ]
机构
[1] Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37830 USA
[2] US FDA, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
[3] McGill Univ, Dept Civil Engn & Appl Mech, 817 Sherbrooke St West, Montreal, PQ H3A 0C3, Canada
关键词
Flush list; Pharmaceuticals; Opioids; Environmental impact; Disposal; Wastewater; PERSONAL CARE PRODUCTS; EPIDEMIOLOGY MASS BALANCES; WASTE-WATER EFFLUENT; SEPTIC SYSTEMS; SURFACE WATERS; NONMEDICAL USE; DISPOSAL; ZEBRAFISH; METHADONE; MODEL;
D O I
10.1016/j.scitotenv.2017.05.269
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
A select few prescription drugs can be especially harmful and, in some cases, fatal with just one dose when not used as prescribed. Therefore, the U.S. Food and Drug Administration (FDA) recommends that expired, unwanted, or otherwise unused portions of most of these drugs be disposed of quickly through a take-back program. If such an option is not readily available, FDA recommends that they be flushed down the sink or toilet. The goal of the current investigation was to evaluate the ecological and human-health risks associated with the environmental release of the 15 active pharmaceutical ingredients (APIs) currently on the FDA "flush list". The evaluation suggests that even when highly conservative assumptions are used-including that the entire API mass supplied for clinical use is flushed, all relevant sources in addition to clinical use of the API are considered, and no metabolic loss, environmental degradation, or dilution of wastewater effluents are used in estimating environmental concentrations-most of these APIs present a negligible eco-toxicological risk, both as individual compounds and as a mixture. For a few of these APIs, additional eco-toxicological data will need to be developed. Using similar conservative assumptions for human-health risks, all 15 APIs present negligible risk through ingestion of water and fish. Published by Elsevier B.V.
引用
收藏
页码:1023 / 1040
页数:18
相关论文
共 50 条
  • [2] Overview of the US Food and Drug Administration Center for Veterinary Medicine environmental risk assessment process for veterinary pharmaceuticals
    Zahner, Holly M.
    Hunter, Wesley
    Silberhorn, Eric
    Eirkson, Charles
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [3] US food and drug administration
    Goodman, Jesse
    ONCOLOGY-NEW YORK, 2006, 20 (08): : 946 - 946
  • [4] US Food and Drug Administration
    Blumenthal, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S37 - S37
  • [5] US Food and Drug Administration analysis of strokes associated with raloxifene
    Wyeth, Jo
    Green, Lanh
    Avigan, Mark
    OBSTETRICS AND GYNECOLOGY, 2007, 109 (04): : 999 - 999
  • [6] Food safety/food security aspects related to the environmental release of pharmaceuticals
    Brambilla, Gianfranco
    Testa, Cecilia
    CHEMOSPHERE, 2014, 115 : 81 - 87
  • [7] US Food and Drug Administration Updates
    Sahin, L.
    BIRTH DEFECTS RESEARCH, 2018, 110 (09): : 748 - 748
  • [8] Transparency at the US Food and Drug Administration
    Califf, Robert M.
    JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 24 - 28
  • [9] Independence at the US Food and Drug Administration
    不详
    LANCET, 2006, 367 (9523): : 1630 - 1630
  • [10] Urokinase and the US food and drug administration
    Ouriel, K
    JOURNAL OF VASCULAR SURGERY, 1999, 30 (05) : 957 - 958